279 abstracts found.



Management squamous cell carcinoma unknown primary head and neck (SCCUP) using contemporary diagnostic and radiotherapy (RT) techniques

Year:

Session type:

Theme:

Claire Paterson1,Robin Crosbie1,Philip McLoone2,Derek Grose1,Allan James1,Carolynn Lamb1,Mohammed Rizwanullah3,Stefano Schipani1,Christina Wilson1,Frances Campbell1,Fiona Easton4,Maureen Thomson1
1NHS,2University of Glasgow,3N/A,4CRUK

Efficacy of the Porcupine inhibitor RXC004 in genetically-defined tumour types

Year:

Session type:

Theme:

Simon Woodcock1,Catherine Eagle1,Alicia Edmenson Cook1,Richard Armer1,Inder Bhamra1,Caroline Phillips1
1Redx Pharma

Real-world experience with eribulin for metastatic breast cancer (MBC) in a Scottish population

Year:

Session type:

Theme:

Mark Baxter1,Caroline Lowrie1,Sarah Slater1,Rosemary Stevens1,Iain Macpherson2
1Beatson West of Scotland Cancer Centre,2University of Glasgow

Hospital admissions with Immunotherapy toxicities in melanoma patients on Ipilimumab and Nivolumab

Year:

Session type:

Theme:

Maria Martinez1,Cathy Johnston1,Ghada Al-Salih1,Julie Clarke1,Roisin O'Donoghue1,TR. Jeffrey Evans1,Ashita Waterston1
1NHS

External beam radiotherapy for older people with endometrial cancer

Year:

Session type:

Theme:

Cicely Cunningham1,Azmat Sadozye1,Rosie Harrand2,Nicholas Reed3,Kathryn Graham4
1Beatson West of Scotland Cancer Centre,2Beatson West of Scotland,3Beatson West of Scotland Cancer,4Beatson West of Scotland Cancer Cent

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)

Year:

Session type:

Theme:

Jeffrey S. Weber1,Mario Mandala2,Michele Del Vecchio3,Helen Gogas4,Ana M. Arance5,C. Lance Cowey6,Stéphane Dalle7,Michael Schenker8,Vanna Chiarion-Sileni9,Ivan Marquez-Rodas10,Jean-Jacques Grob11,Marcus Butler12,Mark R. Middleton13,Michele Maio14,Victoria Atkinson15,Reinhard Dummer16,Veerle de Pril17,Anila Qureshi17,James Larkin18,Paolo A. Ascierto19
1NYU Perlmutter Cancer Center,2Papa Giovanni XXIII Hospital,3Medical Oncology, National Cancer Institute,4University of Athens,5Hospital Clinic de Barcelona,,6Texas Oncology–Baylor Charles A. Sammons Cancer Center,7Hospices Civils de Lyon,8Oncology Center Sf Nectarie Ltd.,9Oncology Institute of Veneto IRCCS,10Hospital Gregorio Marañón,,11Hôpital de la Timone,12Princess Margaret Cancer Centre,13Churchill Hospital,14Center for Immuno-Oncology, University Hospital of Siena,15Gallipoli Medical Research Foundation and University of Queensland,16University Hospital of Zurich,17Bristol-Myers Squibb,18The Royal Marsden NHS Foundation Trust,19Istituto Nazionale Tumori Fondazione Pascale

Prehabilitation is feasible during neoadjuvant chemoradiotherapy and may minimize physical deterioration: Results from The REx randomised controlled trial.

Year:

Session type:

Theme:

Susan Moug1,Nanette Mutrie2,Sarah Barry3,Graham Mackay1,Robert Steele4,Charles Boachie3,Annie Anderson4
1NHS Greater Glasgow and Clyde,2University of Edinburgh,3University of Glasgow,4University of Dundee

Curcumin sensitizes kidney cancer cells to TRAIL-induced apoptosis via ROS-mediated link between Endoplasmic Reticulum stress and MAPK activation

Year:

Session type:

Theme:

Ismael Obaidi1,Michael Higgins2,Tara McMorrow3
1University of Babylon,2Bayer Ltd,3UCD center for Toxicology/ University College Dublin

Defining enhanced recovery in peri-hilar cholangiocarcinoma resection.

Year:

Session type:

Theme:

Leonard Quinn1,Kulbir Mann2,Abdullah Malik1,Nicholas Bird2,Robert Jones1,Declan Dunne3,Stefan Stremitzer2,Carmen Lacasia-Purroy2,Graeme Poston2,Stephen Fenwick2,Hassan Malik2
1University of Liverpool,2University Hospital Aintree,3Royal Liverpool University Hospital

Investigation of anticancer activity of Recombinant OPCML (rOPCML) in ovarian cancer and glioblastoma cell lines

Year:

Session type:

Theme:

Claudia von Arx1,Yuewei Xu1,Nelofer Syed1,Chiara Recchi1,Kevin O'Neill1,Manuela Mura1,Hani Gabra2
1Imperial College London,2Imperial College London - AstraZeneca

Utilisation of PET-CT Following Chemoradiation for Locally Advanced Head and Neck Cancer.

Year:

Session type:

Theme:

Mark Winton1,Joanna Mackenzie1,Devraj Srinivasan1,Martin Doak1
1NHS Lothian

Analysis of SWI/SNF catalytic subunits mutations and drug sensitivity in colorectal cancer.

Year:

Session type:

Theme:

Sarah EL-Zahab1
1University of Sussex

Is there a role for a biological boost in squamous cell anal cancer?

Year:

Session type:

Theme:

Rebecca Muirhead1,Ahmad Sabbagh2,Clare Jacobs2,Rosie Cooke3,Kwun-Ye Chu3,Stasya M Ng4,Victoria Y. Strauss5,Pradeep S. Virdee5,Maria A. Hawkins6,Marianne C. Aznar7,Rebecca Muirhead2
1NHS,2Department of Oncology, Oxford University Hospitals NHS Foundation Trust,3Department of Oncology, Oxford University Hospitals NHS Foundation Trust and CRUK MRC Oxford Institute for Radiation Oncology, University of Oxford,4Oncology Clinical Trials Office, Department of Oncology, University of Oxford,5Centre for Statistics in Medicine, NDORMS, University of Oxford,6CRUK MRC Oxford Institute for Radiation Oncology, University of Oxford,7Manchester Cancer research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester

Clinicopathological significance of ligase I, III & IV in Epithelial Ovarian Cancers

Year:

Session type:

Theme:

M L Alabdullah1,A Alblihy2,R Ali3,P Moseley4,S Chan4,E Rakha2,S Madhusudan4
1university of nottingham,2University of Nottingham,3University of Nottigham,4Nottingham University Hospitals

Clinical and outcome significance of positive AKT expression in epithelial ovarian cancer

Year:

Session type:

Theme:

M L Alabdullah1,A Alblihy2,P Moseley3,S Madhusudan3,S Chan3,E Rakha2
1university of nottingham,2University of Nottingham,3Nottingham University Hospitals

Hepatic resection following selective internal radiotherapy in the FOXFIRE clinical trial: survival, safety, and histopathology

Year:

Session type:

Theme:

Pradeep S. Virdee1,Helen Winter2,Joe Rassam3,Rob Goldin3,Harpreet S. Wasan4,Ricky A. Sharma5
1Centre for Statistics in Medicine, University of Oxford,2Green Templeton College, University of Oxford,3Centre for Pathology, Imperial College,4Imperial College Healthcare NHS Trust and Imperial College, Hammersmith Hospital,5University College London Hospitals Biomedical Research Centre, UCL Cancer Institute

National cohort evaluation of Capecitabine vs. 5-Fluorouracil as concurrent therapy with Mitomycin-C & intensity modulated radiotherapy in the radical treatment of anal cancer

Year:

Session type:

Theme:

Christopher Jones1,Richard Adams2,Amy Downing1,Rob Glynne-Jones3,Mark Harrison3,Maria Hawkins4,David Sebag-Montefiore1,Duncan Gilbert5,Rebecca Muirhead6
1University of Leeds,2Centre for Trials Research, Cardiff University,3Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital,4CRUK MRC Oxford Institute for Radiation Oncology, University of Oxford,5Sussex Cancer Centre, Royal Sussex County Hospital,6Oxford Cancer & Haematology Centre, Oxford University Hospitals

Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN)

Year:

Session type:

Theme:

Charleen Chan Wah Hak1,Christopher Coyle1,Arwa Kocache1,Delia Short1,Naveed Sarwar1,Michael Seckl1,Michael Gonzalez1
1Charing Cross Hospital, Imperial College Healthcare NHS Trust, London

Trifluridine and Tipiracil (Lonsurf) for Advanced Colorectal Cancer: Response rates and Survival Data from a UK Tertiary Cancer Centre.

Year:

Session type:

Theme:

Joanna Connor1
1Clatterbridge Cancer Centre

Outcome of remission induction in childhood acute lymphoblastic leukemia treated with modified BFM-90 protocol and UKALL 2011 interim guidelines, Single Centre experience from Pakistan

Year:

Session type:

Theme:

Safia Khan1,Muhammad Latif2,Mazin Sirelkhatim3,Faisal Azam2
1The Children's Hospital & ICH, Lahore,2king Fahad Specialist Hospital,3North Wales Cancer Treatment Centre

A review of the advice and service provided by AOS for patients on immunotherapy at Velindre Cancer Centre

Year:

Session type:

Theme:

Joanita Ocen1,Joanita Ocen2,Hayley Taylor3,Hilary Williams2
1South West Wales Cancer Centre,2Velindre Cancer Centre,3Cardiff Medical School

Activation of AMPK sensitizes prostate cancer cells to experimental radiotherapy

Year:

Session type:

Theme:

Colin Rae1,Robert Mairs1
1University of Glasgow

Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer

Year:

Session type:

Theme:

Simon Lord1,Wei-Chen Cheng1,Dan Liu1,Edoardo Guade2,Syed Haider3,Tom Metcalf4,Neel Patel1,Fergus Gleeson1,Alastair Thompson5,Michael Pollak6,Roy Pankaj7,Christian Frezza8,John Fenwick4,Franceca Buffa1,Adrian Harris1
1University of Oxford,2University of Cambridge,3Institute of Cancer Research,4University of Liverpool,5MD Anderson Cancer Centre,6McGill University,7Oxford University Hospitals NHS Foundation Trust,8University of Cambridage

The link between CXCL9 and tumour infiltration of lymphoid populations in liver metastases

Year:

Session type:

Theme:

Dalal Almuaili1,Fiona Hand2,Cathal Harmon1,Elizabeth Ryan3,Niamh Nolan2,Justin Geoghegan2,Cliona O’Farrelly1
1trinity college dublin,2St Vincent's university hospital,3university college dublin

A role for NRF-2 in the mechanism of action and effectiveness of dual tyrosine kinase inhibitor, lapatinib, in breast cancer cells

Year:

Session type:

Theme:

Poornima Paramasivan1,Simon Langdon2,Yusuf Deeni1
1University of Abertay Dundee,2University of Edinburgh

FAK-PD1: A phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition

Year:

Session type:

Theme:

Stefan Symeonides1,Dean Fennell2,Christian Ottensmeier3,Rachel Nirsimloo4,Pavlina Spiliopoulou5,Harriet Walter2,Richard Wilson6,Alan Serrels7,Fiona Thomson8,Dawn Currie9,Susan Dillon9,James Paul9,Vicky Coyle6,T.R. Jeffry Evans5
1University of Edinburgh & Edinburgh Cancer Centre,2University of Leicester & University Hospitals of Leicester NHS Trust,3University of Southampton & Southampton University Hospitals NHS Trust,4Edinburgh Cancer Centre, NHS Lothian,5University of Glasgow & Beatson West of Scotland Cancer Centre,6Queen's University Belfast & Northern Ireland Cancer Centre,7MRC Centre for Inflammation Research, University of Edinburgh,8Translational Pharmacology Laboratory, University of Glasgow,9Cancer Research UK Clinical Trials Unit, University of Glasgow

A Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle Toxin Conjugate) given intravenously in patients with advanced solid tumours

Year:

Session type:

Theme:

Udai Banerji1,Natalie Cook2,T.R. Jeffry Evans3,Irene Moreno Candilejo1,Patricia Roxburgh3,Claire Kelly2,Narmatha Sabaratnam1,Rashmi Passi1,Sawretse Leslie4,Sidath Katugampola4,Lisa Godfrey4,Neil Tremayne4,Gavin Halbert5,Gavin Bennett6,Maria Koehler6,Gillian Langford6,Marc Pittman4,Stefan Symeonides7
1Institute of Cancer Research & Royal Marsden NHS Foundation Trust,2University of Manchester & Christie NHS Foundation Trust,3University of Glasgow & Beatson West of Scotland Cancer Centre,4Cancer Research UK Centre for Drug Development,5Cancer Research UK Formulation Unit, University of Strathclyde,6Bicycle Therapeutics,7Cancer Research UK Centre for Drug Development & University of Edinburgh

Validation of a predictive clinical risk model for acute skin toxicity in patients undergoing breast radiotherapy

Year:

Session type:

Theme:

Tim Rattay1,Kerstie Johnson2,R Paul Symonds1,Jenny Chang-Claude3,Petra Seibold3,Gillian Barnett4,Charlotte Coles4,Catharine West5,Christopher Talbot1
1University of Leicester,2Nottingham University Hospitals NHS Trust,3DKFZ German Cancer Research Institute,4Cambridge University Hospitals NHS Trust,5University of Manchester

Defining DDR deficiency and replication stress in pancreatic cancer

Year:

Session type:

Theme:

Stephan Dreyer1,Viola Paulus-Hock2,Eirini-Maria Lampraki1,Rosanna Upstill-Goddard1,Giusseppina Caligiuri1,Holly Brunton3,Bryan Serrels1,Richard Cunningham1,Nigel Jamieson1,Colin McKay1,Peter Bailey1,Susie Cooke1,Andrew Biankin1,David Chang1
1University of Glasgow,2Beatson Institute of Cancer Research,3University of GLasgow